Quantification of PD-L1 Expression with 18F-BMS-986192 PET/CT in Patients with Advanced-Stage Non-Small Cell Lung Cancer

Conclusion: A single-tissue reversible model can be used to quantify tumor uptake of the PD-L1 PET tracer 18F-BMS-986192. SUV at 60 min after injection, normalized for body weight, is an accurate simplified parameter for uptake assessment of baseline studies. To assess its predictive value for response evaluation during programmed cell death protein 1 or PD-L1 immune checkpoint inhibition, further validation of SUV against VT based on an image-derived input function is recommended.

Source: Journal of Nuclear Medicine - September 30, 2020 Category: Nuclear Medicine Authors: Huisman, M. C., Niemeijer, A.-L. N., Windhorst, A. D., Schuit, R. C., Leung, D., Hayes, W., Poot, A., Bahce, I., Radonic, T., Oprea-Lager, D. E., Hoekstra, O. S., Thunnissen, E., Hendrikse, N. H., Smit, E. F., de Langen, A. J., Boellaard, R. Tags: Clinical Source Type: research